-
1
-
-
33745227399
-
Cyclophosphamide versus placebo in scleroderma lung disease
-
Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
-
(2006)
N Engl J Med
, vol.354
, pp. 2655-2666
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
-
2
-
-
0021256105
-
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
-
Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
-
(1984)
Chest
, vol.85
, pp. 751-758
-
-
Mahler, D.A.1
Weinberg, D.H.2
Wells, C.K.3
Feinstein, A.R.4
-
3
-
-
34248589179
-
Impact of oral cyclophosphamide on healthrelated quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study
-
Khanna D, Yan X, Tashkin DP et al. Impact of oral cyclophosphamide on healthrelated quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007;56:1676-84.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1676-1684
-
-
Khanna, D.1
Yan, X.2
Tashkin, D.P.3
-
4
-
-
13444252280
-
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the Scleroderma Lung Study
-
Khanna D, Clements PJ, Furst DE et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 592-600
-
-
Khanna, D.1
Clements, P.J.2
Furst, D.E.3
-
5
-
-
0024852022
-
Measurement of health status. Ascertaining the minimal clinically important difference
-
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
-
(1989)
Control Clin Trials
, vol.10
, pp. 407-415
-
-
Jaeschke, R.1
Singer, J.2
Guyatt, G.H.3
-
6
-
-
0018887574
-
-
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis scleroderma, Arthritis Rheum 1980;23:581-90
-
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
-
-
-
-
7
-
-
34547408278
-
Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
-
Khanna D, Furst DE, Wong WK et al. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res 2007;16: 1083-92.
-
(2007)
Qual Life Res
, vol.16
, pp. 1083-1092
-
-
Khanna, D.1
Furst, D.E.2
Wong, W.K.3
-
8
-
-
33750367940
-
Minimally important difference in diffuse systemic sclerosis- results from the D-Penicillamine Study
-
Khanna D, Furst DE, Hays RD et al. Minimally important difference in diffuse systemic sclerosis- results from the D-Penicillamine Study. Ann Rheum Dis 2006; 65:1325-9.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1325-1329
-
-
Khanna, D.1
Furst, D.E.2
Hays, R.D.3
-
9
-
-
33846952106
-
Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis
-
Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007;34:280-9.
-
(2007)
J Rheumatol
, vol.34
, pp. 280-289
-
-
Wells, G.1
Li, T.2
Maxwell, L.3
Maclean, R.4
Tugwell, P.5
-
10
-
-
0037368520
-
Meaningful effect size and patterns of response of the transition dyspnea index
-
Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003;56:248-55.
-
(2003)
J Clin Epidemiol
, vol.56
, pp. 248-255
-
-
Witek Jr, T.J.1
Mahler, D.A.2
-
11
-
-
40649117704
-
Outcomes for COPD pharmacological trials: From lung function to biomarkers
-
Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
-
(2008)
Eur Respir J
, vol.31
, pp. 416-469
-
-
Cazzola, M.1
MacNee, W.2
Martinez, F.J.3
-
12
-
-
20144382504
-
Approaches and recommendations for estimating minimally important differences for health-related quality of life measures
-
Hays RD, Farivar S, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2005;2:63-7.
-
(2005)
COPD
, vol.2
, pp. 63-67
-
-
Hays, R.D.1
Farivar, S.2
Liu, H.3
-
13
-
-
37549004786
-
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
-
Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9.
-
(2008)
J Clin Epidemiol
, vol.61
, pp. 102-109
-
-
Revicki, D.1
Hays, R.D.2
Cella, D.3
Sloan, J.4
-
14
-
-
57349181492
-
The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice
-
Khanna D, Pope JE, Khanna PP et al. The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. J Rheumatol 2008;35:2339-43.
-
(2008)
J Rheumatol
, vol.35
, pp. 2339-2343
-
-
Khanna, D.1
Pope, J.E.2
Khanna, P.P.3
-
15
-
-
42449112005
-
Development of a provisional core set of response measures for clinical trials of systemic sclerosis
-
Khanna D, Lovell DJ, Giannini E et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67:703-9.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 703-709
-
-
Khanna, D.1
Lovell, D.J.2
Giannini, E.3
|